sitravatinib
sitravatinib: developed by 1 company · 6 clinical trials tracked.
sitravatinib evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
How could sitravatinib → MRTX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Mirati Therapeutics, Inc. (MRTX) Metastatic Non-Squamous Non-Small Cell Lung Cancer; Advanced… | Phase 3 |
Clinical Trials (6)
Phase II, Open-Label Study of Preliminary Efficacy of Sitravatinib in Combination With Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
Primary endpoint: Objective Response Rate (ORR)
Phase 2 Trial of Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer
Primary endpoint: Objective Response Rate (ORR)
A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
Primary endpoint: Frequency of subjects experiencing treatment-related AEs.
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies
Primary endpoint: Number of Participants with Immune-Mediated Adverse Events, Serious Adverse Events, and Adverse Events Grade 3 or Higher
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE
Primary endpoint: Overall Survival (OS)
National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer
Primary endpoint: Objective response (OR)
Frequently asked questions
Who is developing sitravatinib?
sitravatinib is being developed by Mirati Therapeutics, Inc..
How many clinical trials involve sitravatinib?
BioSniper tracks 6 clinical trials involving sitravatinib.